Black Diamond Therapeutics Inc
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
Higher fair value for undervalued wide moat share
stocks
Fears of deteriorating loan quality sends bank share plummeting
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.50 | 1.10 | -0.01% |
| CAC 40 | 8,384.87 | 46.74 | -0.55% |
| DAX 40 | 24,671.22 | 323.61 | -1.29% |
| Dow JONES (US) | 51,876.11 | 44.51 | -0.09% |
| FTSE 100 | 10,508.02 | 21.87 | -0.21% |
| HKSE | 23,048.45 | 376.59 | 1.66% |
| NASDAQ | 25,297.62 | 60.99 | -0.24% |
| Nikkei 225 | 68,761.84 | 599.04 | -0.86% |
| NZX 50 Index | 13,539.89 | 44.65 | 0.33% |
| S&P 500 | 7,354.02 | 3.47 | -0.05% |
| S&P/ASX 200 | 8,775.20 | 1.70 | -0.02% |
| SSE Composite Index | 4,032.52 | 5.25 | 0.13% |